Insights From Our Labs to Yours https://ddblog.labcorp.com Labcorp Blog Tue, 03 Oct 2023 15:16:38 +0000 en-US hourly 1 https://wordpress.org/?v=5.4 https://ddblog.labcorp.com/wp-content/uploads/2021/06/favicon-60x60.ico Insights From Our Labs to Yours https://ddblog.labcorp.com 32 32 176650705 UK-REACH Planning https://ddblog.labcorp.com/2023/10/uk-reach-planning/ Mon, 02 Oct 2023 18:06:53 +0000 https://ddblog.labcorp.com/?p=9208 Introduction and U.K.’s exit from the EU On leaving the EU, EU-REACH legislation was copied over into UK-REACH as of 01 January 2020. Applying to only England, Wales and Scotland (collectively referred to as Great Britain or GB), Northern Ireland continues to be regulated by EU-REACH. The UK-REACH transitional arrangements …

The post UK-REACH Planning appeared first on Insights From Our Labs to Yours.

]]> 9208 Top considerations for developing a biomarker solution and CDx strategy https://ddblog.labcorp.com/2023/07/top-considerations-for-developing-a-biomarker-solution-and-cdx-strategy/ Wed, 19 Jul 2023 18:11:32 +0000 https://ddblog.labcorp.com/?p=9197 When it comes to designing clinical trials with expedience and efficiency, many drug developers are choosing biomarker-driven strategies for their investigational precision medicines. As key features of developing new therapies and diagnostics, biomarkers define the disease biology, provide potential targets for new therapies and provide strong potential for market differentiation. …

The post Top considerations for developing a biomarker solution and CDx strategy appeared first on Insights From Our Labs to Yours.

]]> 9197 How to de-risk OECD 443 studies through optimized dose level selections https://ddblog.labcorp.com/2023/06/how-to-de-risk-oecd-443-studies-through-optimized-dose-level-selections/ Mon, 05 Jun 2023 20:42:11 +0000 https://ddblog.labcorp.com/?p=9185 The European Chemicals Agency (ECHA) recently conducted a review project regarding the design of the OECD 443 (Extended One-Generation Reproductive Toxicity Study, or EOGRTS). The project’s goal was to assess the performance of the study in terms of study design, conduct and findings to determine if the study design currently …

The post How to de-risk OECD 443 studies through optimized dose level selections appeared first on Insights From Our Labs to Yours.

]]> 9185 What does a central lab do? 4 core services to know https://ddblog.labcorp.com/2023/04/what-does-a-central-lab-do-4-core-services-to-know/ Mon, 24 Apr 2023 17:53:49 +0000 https://ddblog.labcorp.com/?p=9181 Every clinical trial relies on data from its study participants to inform decisions regarding the safety and efficacy of a potential new treatment. Clinical trial sponsors rely on the data from laboratory tests to bring clear insights that advance studies. Labcorp Central Laboratory Services generates more clinical trial data than …

The post What does a central lab do? 4 core services to know appeared first on Insights From Our Labs to Yours.

]]> 9181 Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework https://ddblog.labcorp.com/2023/04/faster-access-to-biopesticide-alternatives-to-conventional-pesticides-under-the-u-s-bppd-regulatory-framework/ Thu, 20 Apr 2023 16:05:48 +0000 https://ddblog.labcorp.com/?p=9170 There is pressure worldwide for better, faster access to biological alternatives to conventional crop protection chemicals (CPCs). The U.S. Environmental Protection Agency (EPA) is ahead of regions such as the European Union (EU) in revising its regulatory approaches for biopesticides and in having a division dedicated to them, namely, the …

The post Faster access to biopesticide alternatives to conventional pesticides under the U.S. BPPD regulatory framework appeared first on Insights From Our Labs to Yours.

]]> 9170 Alcohol-related liver disease: Inherent Challenges and Strategies for Successful Clinical Trial Conduct https://ddblog.labcorp.com/2023/04/alcohol-related-liver-disease-inherent-challenges-and-strategies-for-successful-clinical-trial-conduct/ Mon, 17 Apr 2023 14:09:21 +0000 https://ddblog.labcorp.com/?p=9174 The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an …

The post Alcohol-related liver disease: Inherent Challenges and Strategies for Successful Clinical Trial Conduct appeared first on Insights From Our Labs to Yours.

]]> 9174 Program management services are now offered as part of Labcorp’s Preclinical Oncology Services https://ddblog.labcorp.com/2023/03/program-management-services-are-now-offered-as-part-of-labcorps-preclinical-oncology-services/ Wed, 08 Mar 2023 14:54:36 +0000 https://ddblog.labcorp.com/?p=9147 When it comes to discoveries in oncology, cancer patients can’t wait, which means neither can you. At Labcorp Preclinical Oncology, we understand there are many steps, phases and regulations to wade through to get to a lead drug candidate—all while time is of the utmost importance. We are excited to …

The post Program management services are now offered as part of Labcorp’s Preclinical Oncology Services appeared first on Insights From Our Labs to Yours.

]]> 9147 Enabling better access to kidney disease trials https://ddblog.labcorp.com/2023/03/enabling-better-access-to-kidney-disease-trials/ Tue, 07 Mar 2023 14:27:42 +0000 https://ddblog.labcorp.com/?p=9138 March is National Kidney Month, and we at Labcorp are committed to improving the renal health of patients worldwide. The field of nephrology clinical research has been steadily adding new interventional trials over the last five years at an average pace of 176 trials per year. This activity reflects the …

The post Enabling better access to kidney disease trials appeared first on Insights From Our Labs to Yours.

]]> 9138 Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America https://ddblog.labcorp.com/2023/02/innovative-collaboration-between-biomakers-and-labcorp-to-provide-greater-access-to-oncology-patients-in-latin-america/ Fri, 17 Feb 2023 18:43:48 +0000 https://ddblog.labcorp.com/?p=9144 In December 2022, Labcorp and Biomakers signed an agreement that will positively impact thousands of cancer patients in Latin America through greater access to diagnostic molecular profiling and participation in clinical trials. We recently asked Nicolas Kirchuk (NK), CEO and co-founder of Biomakers, and Isagani Chico (IC), MD, VP, global …

The post Innovative collaboration between Biomakers and Labcorp to provide greater access to oncology patients in Latin America appeared first on Insights From Our Labs to Yours.

]]> 9144 Delivering solutions to the next generation of cardiovascular medicines https://ddblog.labcorp.com/2023/02/delivering-solutions-to-the-next-generation-of-cardiovascular-medicines/ Mon, 06 Feb 2023 14:29:44 +0000 https://ddblog.labcorp.com/?p=9124 JB Flinders, Senior Director, CVMER, Operational Strategy and Planning and Peter Alfinito, Executive Director, CVMER, Operational Strategy and Planning February is American Heart Month, and we at Labcorp are dedicated to improve the cardiovascular health of patients worldwide, as part of Labcorp’s mission to improve health and improve lives. This …

The post Delivering solutions to the next generation of cardiovascular medicines appeared first on Insights From Our Labs to Yours.

]]> 9124